. Author manuscript; available in PMC: 2021 Aug 15.

Published in final edited form as: Clin Cancer Res. 2020 Nov 18;27(4):975–982. doi: 10.1158/1078-0432.CCR-20-3646

Table 2.

Predictors of pCR on Univariate analysis

	pCR n/N	OR	95% CI	P^a
Age
≤50 y	25/45	1	0.40–1.97	0.778
>50 y	29/55	0.89	0.40–1.97	0.778
Lymph node status
Negative	38/70	1	0.41–2.27	0.930
Positive	16/30	0.96	0.41–2.27	0.930
T stage
T 1-2	50/89	1	0.12–1.63	0.222
T 3-4	4/11	0.45	0.12–1.63	0.222
TNM stage
I/II	46/86	1	0.37–3.63	0.799
III	8/14	1.16	0.37–3.63	0.799
gBRCA mutation^b
Negative	32/65	1	0.99–11.37	0.052
Positive	13/17	3.35	0.99–11.37	0.052
Histological grade
Grade 1/2	3/13	1	1.21–18.38	0.025
Grade 3	51/87	4.72	1.21–18.38	0.025
sTILs^c
<20%	25/51	1	0.88–4.93	0.096
≥20%	26/39	2.08	0.88–4.93	0.096
Study arm
Arm A	26/48	1	0.45–2.17	0.974
Arm B	28/52	0.99	0.45–2.17	0.974

Odds ratios (ORs) and 2-sided p-values by logistic regression.

gBRCA mutation data available for N=82 patients (40 in Arm A, 42 in Arm B).

sTILs data available for N=90 patients (42 in Arm A, 48 in Arm B).

Abbreviations: OR, odds ratio; pCR, pathological complete response; sTILs, stromal tumor-infiltrating lymphocytes.